Obagi Nu-Derm System
Prescription tretinoin + hydroquinone medical-grade skincare system
About This Treatment
Obagi Nu-Derm is a prescription-grade comprehensive skincare system centered on tretinoin (0.025-0.1%) and 4% hydroquinone.
Physician-supervised phased program achieving simultaneous epidermal turnover normalization, dermal collagen synthesis, and melanin suppression. 24-week RCT (387 subjects) demonstrated superiority over tretinoin alone or hydroquinone alone.
Mechanism of Action
Tretinoin (all-trans retinoic acid) directly binds nuclear RAR receptors with 10-20x retinol activity, promoting COL1A1 transcription while suppressing MMP-1 by 70-80%. Accelerates epidermal turnover to 14-21 days. Hydroquinone (4%) competitively binds tyrosinase copper active site, inhibiting the tyrosine→DOPA→dopaquinone cascade and selectively destroying existing melanosomes.
Indications
Expected Results
24-week RCT (387 subjects): increased epidermal thickness, significant pigmentation reduction, statistically significant improvements in perioral wrinkles, skin laxity, mottled hyperpigmentation, and dermal thickness (P≤0.05). Significantly superior to 0.1% tretinoin alone, 4% HQ alone, and OTC products.
Clinical Evidence
Risks & Side Effects
High-frequency retinoid dermatitis. HQ contact dermatitis. Risk of exogenous ochronosis with prolonged high-concentration HQ use. 3-6 month drug holiday recommended. Contraindicated in pregnancy. Strict sun protection.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition